Search results for "PSO"

showing 10 items of 679 documents

Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis

2008

Psoriasis and psoriatic arthritis are common diseases associated with considerable morbidity and disability. Their pathophysiology comprises similar processes leading to inflammation of skin, entheses, and joints. Although traditional systemic agents can be effective, their use may be limited by lack of efficacy and concerns regarding adverse effects. The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive reg…

AdultMalemedicine.medical_specialtyAnti-Inflammatory AgentsArthritisDermatologyAntibodies Monoclonal HumanizedSeverity of Illness IndexPsoriasis Psoriatic ArthritisPsoriatic arthritisPsoriasisSeverity of illnessSettore MED/35 - Malattie Cutanee E VenereemedicineAdalimumabHumansPsoriasisAdverse effectTumor Necrosis Factor-alphabusiness.industryArthritis PsoriaticAdalimumabAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseDermatologyRadiographyClinical trialTreatment OutcomeMonoclonalFemalebusinessmedicine.drugDermatologic Therapy
researchProduct

Prevalence, predictors and comorbidity of dry skin in the general population

2018

Background Dry skin is a frequent and multifaceted condition which can be associated with skin irritation, itch, patient discomfort and manifest skin disease. In spite of being frequent, little is known about the epidemiology of dry skin in the population. Objective To determine the prevalence of dry skin in the German adult population. Methods Data of 48 630 employed persons were assessed on a cross-sectional level in whole-body examinations by experienced dermatologists during company-based skin screenings conducted in 343 German companies. Next to the current dermatologic findings, age, gender, allergies, atopic diseases and the skin type were assessed. Results In total, n = 14 300 perso…

AdultMalemedicine.medical_specialtyCross-sectional studyPopulationPrevalenceDermatologySkin DiseasesDermatitis Atopic030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineGermanyPsoriasisDry skinHypersensitivityPrevalencemedicineHumansPsoriasis030212 general & internal medicineeducationeducation.field_of_studybusiness.industryAge FactorsSeborrhoeic dermatitisAtopic dermatitisMiddle Agedmedicine.diseaseDermatologyComorbidityDermatitis SeborrheicCross-Sectional StudiesInfectious DiseasesFemaleWartsmedicine.symptombusinessJournal of the European Academy of Dermatology and Venereology
researchProduct

Augmented glucose-6-phosphate dehydrogenase activity and normal penetration and metabolism of dehydroepiandrosterone in mononuclear leukocytes in pso…

1986

The aim of the study was to determine a biochemical basis for the augmented oxidative metabolism found in mononuclear leukocytes (MNL) of patients with active psoriasis. Dehydroepiandrosterone (DHEA) is known to inhibit glucose-6-phosphate dehydrogenase (G-6-PDH). We determined the activity of G-6-PDH as well as the penetration and metabolism of DHEA - diminished plasma concentrations of which have been found in psoriatics previously - in 16 patients with active psoriasis and 16 controls. MNL in patients with psoriasis possessed 52% more (p less than 0.05) G-6-PDH activity, based on cell number, and 34% more (p less than 0.05) activity, based on soluble protein. No difference in DHEA penetr…

AdultMalemedicine.medical_specialtyGlucose-6-phosphate dehydrogenase activityDehydroepiandrosteroneDehydrogenaseDermatologyGlucosephosphate DehydrogenasePeripheral blood mononuclear cellMonocyteschemistry.chemical_compoundReference ValuesPsoriasisInternal medicinemedicineGlucose-6-phosphate dehydrogenaseHumansPsoriasisChemistryBiological TransportGeneral MedicinePenetration (firestop)MetabolismDehydroepiandrosteronemedicine.diseaseKineticsEndocrinologyFemaleArchives of dermatological research
researchProduct

Achilles tendon ultrasonography may detect early features of psoriatic arthropathy in patients with cutaneous psoriasis.

2014

SummaryBackground Psoriatic arthropathy is a progressive and debilitating disease involving reduction of functional activity of the articulations with consequent deterioration of the patient's quality of life. The entheses represent the initial site of articular inflammation and the enthesis of the Achilles tendon is the first to be affected. In some patients with psoriasis, enthesitis may not be diagnosed because it is still asymptomatic. Objectives To evaluate whether ultrasonography allows early diagnosis in a larger population and to identify significant alterations of enthesitis beyond increased thickness of the Achilles tendon. Materials and methods The study was undertaken on 59 pati…

AdultMalemedicine.medical_specialtyHeelBursitisPopulationDermatologyAchilles TendonYoung AdultPsoriasismedicineHumansPsoriasiseducationAgedUltrasonographyAchilles tendoneducation.field_of_studybusiness.industryArthritis PsoriaticEnthesitisMiddle Agedmedicine.diseaseEnthesisDermatologyTendonSurgerymedicine.anatomical_structureEarly DiagnosisTendinopathyFemalemedicine.symptombusinessThe British journal of dermatology
researchProduct

Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting.

2019

Itch is the most bothersome symptom in psoriasis, often leading to impaired quality of life. Treatment of psoriasis-induced itch is frequently unsatisfactory as the various therapies employed have a delayed onset of effect. Histamine-1 receptor (H1) antihistamines are not recommended in treatment guidelines as histamine is not considered a key mediator in psoriasis. However, patients using H1 antihistamines frequently report benefits in questionnaire-based studies. To address these contradictions, we examined the short-term effects of levocetirizine, a nonsedating H1 antihistamine, on psoriasis-related itch and itch-related quality of life. In this pilot study, patients with psoriasis-relat…

AdultMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingTime FactorsPilot ProjectsDermatologyLevocetirizine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeimmune system diseasesPsoriasisparasitic diseasesotorhinolaryngologic diseasesMedicineEffective treatmentHumansPsoriasisskin and connective tissue diseasesH1 antihistamineDose-Response Relationship Drugbusiness.industryPruritusDelayed onsetGeneral MedicineMiddle Agedmedicine.diseaseDermatologyeye diseasesCetirizineTreatment Outcome030220 oncology & carcinogenesisConcomitantQuality of LifeFemaleOpen labelbusinessmedicine.drugDermatologic therapyREFERENCES
researchProduct

Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospe…

2019

Background: Biologics for moderate-to-severe psoriasis are expensive and treatment substitutions may vastly increase cost. Moreover, administration regimens in routine practice may differ from recommended guidelines. Objectives: To evaluate long-term effectiveness, regimen, drug-survival, and efficiency of self-administered biologics in clinical practice. Methods: We performed a 5-year retrospective study in 72 patients (44 ± 14 years old) with moderate-to-severe psoriasis at the University Hospital La Plana (Vila-real, Spain), treated with subcutaneous biologics. We determined the effectiveness (PASI 75 or PASI < 5), and drug-survival using Kaplan-Meier estimates, and analyzed reasons for …

AdultMalemedicine.medical_specialtyIndividualized dosingCost effectivenessefficacySelf AdministrationKaplan-Meier EstimateDermatologyRoutine practiceDrug CostsustekinumabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineChart reviewPsoriasisUstekinumabmedicineHumansPsoriasisbiologicsIntensive care medicinecost-effectivenessRetrospective Studies030203 arthritis & rheumatologyBiological ProductsDrug Substitutionbusiness.industryModerate to severe psoriasisAdalimumabpsoriasisanti-TNFpersistenceMiddle Agedmedicine.diseaseUniversity hospitalSpainFemaleUstekinumabbusinessmedicine.drugJournal of Dermatological Treatment
researchProduct

Soluble CD14 monocyte antigen in suction blister fluid and serum of patients with psoriasis.

1993

The purpose of this study was to measure soluble CD14 (sCD14) molecules in the skin and in serum of patients with psoriasis. CD14 is a newly discovered cell surface marker on monocytes that is shed after cell activation. The following procedures were used: suction blisters were raised over the abdominal skin of 9 healthy control individuals and 8 patients with psoriasis. Serum of 17 healthy controls and 17 patients with psoriasis was collected. sCD14 was determined in suction blister fluid and serum by the ELISA technique. The clinical status of psoriasis was rated by the psoriasis area and severity index (PASI score). We found that sCD14 levels in suction blisters of healthy skin (1,050 +/…

AdultMalemedicine.medical_specialtyPathologyAdolescentLipopolysaccharide ReceptorsAntigens Differentiation MyelomonocyticDermatologySuctionGastroenterologySeverity of Illness IndexMonocytesBlisterAntigenPsoriasis Area and Severity IndexAntigens CDPsoriasisImmunopathologyInternal medicinemedicineHumansPsoriasisAgedintegumentary systembusiness.industryMonocyteBlistersMiddle Agedmedicine.diseaseSuction blisterBody Fluidsmedicine.anatomical_structureFemalemedicine.symptomCell activationbusinessDermatology (Basel, Switzerland)
researchProduct

An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis

2015

Background There is an unmet need for long-term, real-life data on the effect of a drug-free interval between treatment cycles in patients with plaque psoriasis being treated with etanercept, which is licensed for intermittent and continuous treatment. Objective The aim of this study was to determine the average duration of the drug-free interval between etanercept treatment cycles in patients with plaque psoriasis. Methods This was a non-interventional, open-label, multicentre, prospective study in patients for whom the decision had already been made to initiate treatment with etanercept during routine practice in German centres. Clinical outcomes were documented over 36 months with study …

AdultMalemedicine.medical_specialtyPopulationDermatologyEtanerceptEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePsoriasis Area and Severity IndexInternal medicinePsoriasisClinical endpointHumansPsoriasisMedicineAdverse effecteducationBody surface areaeducation.field_of_studybusiness.industryDermatology Life Quality IndexMiddle Agedmedicine.diseaseSurgeryInfectious Diseases030220 oncology & carcinogenesisFemalebusinessImmunosuppressive Agentsmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet (R)) versus calcipotriol (Daivonex (R)) in the treatment of …

2007

Objective: A clinical trial was performed to evaluate the efficacy, speed of response, side effects and quality of life of patients treated with calcipotriol/betamethasone dipropionate (Dovobet (R)) for 4 weeks followed by maintenance with calcipotriol for 8 weeks (group A) versus calcipotriol (Daivonex (R)) alone for 12 weeks (group B) for the treatment of psoriasis. Materials and methods: A total of 150 patients were enrolled and randomized to groups A and B. PASI and Skindex-29 were considered the outcome measures. Results: Ninety-six patients completed the trial. At weeks 2 and 4, both groups showed a significant clinical improvement compared to baseline; group A demonstrated a higher c…

AdultMalemedicine.medical_specialtyRandomizationAdolescentskindex-29medicine.drug_classBetamethasone dipropionatecalcipotriol/betamethasone dipropionate; Dovobet; calcipotriol. Daivonex; psoriasis vulgaris; clinical trialDermatologyAdministration CutaneousBetamethasoneSeverity of Illness IndexDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled trialCalcitriolcalcipotriolo/betametasone dipropionatolawPsoriasisInternal medicinepasimedicineHumansPsoriasiscalcipotriolo; calcipotriolo/betametasone dipropionato; pasi; psoriasi; skindex-29CalcipotriolcalcipotriolopsoriasiAgedAged 80 and overAnalysis of Variancebusiness.industrycalcipotriol calcipotriol/betamethasone dipropionate PASI psoriasis Skindex-29 two-compound productMiddle Agedmedicine.diseaseSurgeryClinical trialDrug CombinationsTreatment OutcomechemistryQuality of LifeCorticosteroidBetamethasoneFemaleDermatologic Agentsbusinessmedicine.drug
researchProduct

Photochemotherapy Alone or Combined with Interferon Alpha-2a in the Treatment of Cutaneous T-Cell Lymphoma

1990

Eighty-two patients with either mycosis fungoides (MF) or parapsoriasis en plaques were treated with psoralens ultraviolet A light (PUVA). Clinical and histologic parameters were followed for a period from 6 months to 10 years. Complete clinical clearing of lesions was observed in 51 patients (62%) and most of them were in limited-plaque MF group or parapsoriasis en plaque. The mean total dose of PUVA for complete clearing was less for early MF. Thirty-one patients (38%) relapsed and responded to additional PUVA. Patients in early stages of the disease remained clear for up to 68 months after the first course of PUVA. Post-treatment skin biopsies with early MF showed histologic clearing. A …

AdultMalemedicine.medical_specialtySkin NeoplasmsCombination therapyConstitutional symptomsDermatologyInterferon alpha-2BiochemistryMycosis FungoidesInterferonmedicineHumansSezary SyndromePUVA TherapyMolecular BiologyDepression (differential diagnoses)AgedNeoplasm StagingMycosis fungoidesParapsoriasisbusiness.industryCutaneous T-cell lymphomaInterferon-alphaCell BiologyMiddle Agedmedicine.diseaseCombined Modality TherapyDermatologyRecombinant ProteinsLymphoma T-Cell CutaneousDrug EvaluationFemalebusinessProgressive diseasemedicine.drugJournal of Investigative Dermatology
researchProduct